Role for heparin-binding growth factors in glucose-induced vascular dysfunction

Clifford C. Stephan, Katherine C. Chang, Wanda Lejeune, David Erichsen, Robert J. Bjercke, Ajay Rege, Ronald J. Biediger, Timothy P. Kogant, Tommy A. Brock, Joseph R. Williamson, Ronald Tilton

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Vascular hyperpermeability and excessive neovascularization are hallmarks of early and late vascular endothelial cell dysfunction induced by diabetes. Vascular endothelial growth factor (VEGF) appears to be an important mediator for these early and late vascular changes. We reported previously, using skin chambers mounted on backs of SD rats, that neutralizing antibodies directed against VEGF blocked vascular permeability and blood flow changes induced by elevated tissue glucose and sorbitol levels in a dosage-dependent manner. We report in this study, using the same skin chamber model and neutralizing antibodies directed against basic fibroblast growth factor (FGF-2), that another member of the heparin-binding growth factor family also mediates glucose- and sorbitol-induced vascular permeability and blood flow increases. In addition, we show that 1) TBC1635, a novel heparin-binding growth factor antagonist, blocks the vascular hyperpermeability and blood flow increases induced by elevated tissue levels of glucose and sorbitol and by topical application of VEGF and FGF-2 to granulation tissue in skin chambers, and 2) suramin, a commercially available growth factor antagonist, blocks glucose-induced vascular dysfunction. These results suggest an early role for heparin-binding growth factors in the vascular dysfunction caused by excessive glucose metabolism, possibly via the sorbitol pathway.

Original languageEnglish (US)
Pages (from-to)1771-1778
Number of pages8
JournalDiabetes
Volume47
Issue number11
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Sorbitol
Blood Vessels
Heparin
Fibroblast Growth Factor 2
Intercellular Signaling Peptides and Proteins
Glucose
Vascular Endothelial Growth Factor A
Capillary Permeability
Neutralizing Antibodies
Skin
Suramin
Granulation Tissue
Endothelial Cells

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Stephan, C. C., Chang, K. C., Lejeune, W., Erichsen, D., Bjercke, R. J., Rege, A., ... Tilton, R. (1998). Role for heparin-binding growth factors in glucose-induced vascular dysfunction. Diabetes, 47(11), 1771-1778. https://doi.org/10.2337/diabetes.47.11.1771

Role for heparin-binding growth factors in glucose-induced vascular dysfunction. / Stephan, Clifford C.; Chang, Katherine C.; Lejeune, Wanda; Erichsen, David; Bjercke, Robert J.; Rege, Ajay; Biediger, Ronald J.; Kogant, Timothy P.; Brock, Tommy A.; Williamson, Joseph R.; Tilton, Ronald.

In: Diabetes, Vol. 47, No. 11, 1998, p. 1771-1778.

Research output: Contribution to journalArticle

Stephan, CC, Chang, KC, Lejeune, W, Erichsen, D, Bjercke, RJ, Rege, A, Biediger, RJ, Kogant, TP, Brock, TA, Williamson, JR & Tilton, R 1998, 'Role for heparin-binding growth factors in glucose-induced vascular dysfunction', Diabetes, vol. 47, no. 11, pp. 1771-1778. https://doi.org/10.2337/diabetes.47.11.1771
Stephan CC, Chang KC, Lejeune W, Erichsen D, Bjercke RJ, Rege A et al. Role for heparin-binding growth factors in glucose-induced vascular dysfunction. Diabetes. 1998;47(11):1771-1778. https://doi.org/10.2337/diabetes.47.11.1771
Stephan, Clifford C. ; Chang, Katherine C. ; Lejeune, Wanda ; Erichsen, David ; Bjercke, Robert J. ; Rege, Ajay ; Biediger, Ronald J. ; Kogant, Timothy P. ; Brock, Tommy A. ; Williamson, Joseph R. ; Tilton, Ronald. / Role for heparin-binding growth factors in glucose-induced vascular dysfunction. In: Diabetes. 1998 ; Vol. 47, No. 11. pp. 1771-1778.
@article{02a99f994ee744409913005e584abb3a,
title = "Role for heparin-binding growth factors in glucose-induced vascular dysfunction",
abstract = "Vascular hyperpermeability and excessive neovascularization are hallmarks of early and late vascular endothelial cell dysfunction induced by diabetes. Vascular endothelial growth factor (VEGF) appears to be an important mediator for these early and late vascular changes. We reported previously, using skin chambers mounted on backs of SD rats, that neutralizing antibodies directed against VEGF blocked vascular permeability and blood flow changes induced by elevated tissue glucose and sorbitol levels in a dosage-dependent manner. We report in this study, using the same skin chamber model and neutralizing antibodies directed against basic fibroblast growth factor (FGF-2), that another member of the heparin-binding growth factor family also mediates glucose- and sorbitol-induced vascular permeability and blood flow increases. In addition, we show that 1) TBC1635, a novel heparin-binding growth factor antagonist, blocks the vascular hyperpermeability and blood flow increases induced by elevated tissue levels of glucose and sorbitol and by topical application of VEGF and FGF-2 to granulation tissue in skin chambers, and 2) suramin, a commercially available growth factor antagonist, blocks glucose-induced vascular dysfunction. These results suggest an early role for heparin-binding growth factors in the vascular dysfunction caused by excessive glucose metabolism, possibly via the sorbitol pathway.",
author = "Stephan, {Clifford C.} and Chang, {Katherine C.} and Wanda Lejeune and David Erichsen and Bjercke, {Robert J.} and Ajay Rege and Biediger, {Ronald J.} and Kogant, {Timothy P.} and Brock, {Tommy A.} and Williamson, {Joseph R.} and Ronald Tilton",
year = "1998",
doi = "10.2337/diabetes.47.11.1771",
language = "English (US)",
volume = "47",
pages = "1771--1778",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Role for heparin-binding growth factors in glucose-induced vascular dysfunction

AU - Stephan, Clifford C.

AU - Chang, Katherine C.

AU - Lejeune, Wanda

AU - Erichsen, David

AU - Bjercke, Robert J.

AU - Rege, Ajay

AU - Biediger, Ronald J.

AU - Kogant, Timothy P.

AU - Brock, Tommy A.

AU - Williamson, Joseph R.

AU - Tilton, Ronald

PY - 1998

Y1 - 1998

N2 - Vascular hyperpermeability and excessive neovascularization are hallmarks of early and late vascular endothelial cell dysfunction induced by diabetes. Vascular endothelial growth factor (VEGF) appears to be an important mediator for these early and late vascular changes. We reported previously, using skin chambers mounted on backs of SD rats, that neutralizing antibodies directed against VEGF blocked vascular permeability and blood flow changes induced by elevated tissue glucose and sorbitol levels in a dosage-dependent manner. We report in this study, using the same skin chamber model and neutralizing antibodies directed against basic fibroblast growth factor (FGF-2), that another member of the heparin-binding growth factor family also mediates glucose- and sorbitol-induced vascular permeability and blood flow increases. In addition, we show that 1) TBC1635, a novel heparin-binding growth factor antagonist, blocks the vascular hyperpermeability and blood flow increases induced by elevated tissue levels of glucose and sorbitol and by topical application of VEGF and FGF-2 to granulation tissue in skin chambers, and 2) suramin, a commercially available growth factor antagonist, blocks glucose-induced vascular dysfunction. These results suggest an early role for heparin-binding growth factors in the vascular dysfunction caused by excessive glucose metabolism, possibly via the sorbitol pathway.

AB - Vascular hyperpermeability and excessive neovascularization are hallmarks of early and late vascular endothelial cell dysfunction induced by diabetes. Vascular endothelial growth factor (VEGF) appears to be an important mediator for these early and late vascular changes. We reported previously, using skin chambers mounted on backs of SD rats, that neutralizing antibodies directed against VEGF blocked vascular permeability and blood flow changes induced by elevated tissue glucose and sorbitol levels in a dosage-dependent manner. We report in this study, using the same skin chamber model and neutralizing antibodies directed against basic fibroblast growth factor (FGF-2), that another member of the heparin-binding growth factor family also mediates glucose- and sorbitol-induced vascular permeability and blood flow increases. In addition, we show that 1) TBC1635, a novel heparin-binding growth factor antagonist, blocks the vascular hyperpermeability and blood flow increases induced by elevated tissue levels of glucose and sorbitol and by topical application of VEGF and FGF-2 to granulation tissue in skin chambers, and 2) suramin, a commercially available growth factor antagonist, blocks glucose-induced vascular dysfunction. These results suggest an early role for heparin-binding growth factors in the vascular dysfunction caused by excessive glucose metabolism, possibly via the sorbitol pathway.

UR - http://www.scopus.com/inward/record.url?scp=0031720362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031720362&partnerID=8YFLogxK

U2 - 10.2337/diabetes.47.11.1771

DO - 10.2337/diabetes.47.11.1771

M3 - Article

VL - 47

SP - 1771

EP - 1778

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -